undamentalytics Newsletter
Sign in

Verastem, Inc. income statement

In fiscal 2025, Verastem, Inc. reported revenue of $30.9m, up 209.1% on the year before, operating income of −$170m (a -550.3% margin) and net income of −$209m, or −$3.02 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222024Dec 20242025Dec 2025LTMJun 2026
Revenue27178923103188
Cost of revenue0———————
Gross profit27———————
Research and development444641395181115140
Selling, general and administrative77101632425448195
Operating income−95−132−49−61−73−115−170−160
Interest expense62116102511
Income before tax−72−149−68−71−74−130−209—
Income tax000000——
Net income−72−149−68−71−74−131−209−203
Diluted EPS−$0.02−$0.02−$0.01−$2.45−$2.29−$1.83−$3.02−$2.33
Diluted shares (average)5,783m6,221m13m29m32m71m69m87m
EBITDA−94−132−49−61−73−115−170—

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BCYC vs VSTMFDMT vs VSTMPLX vs VSTM

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Verastem, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Verastem, Inc.